D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects

被引:20
作者
Broich, K
Grunwald, F
Kasper, S
Klemm, E
Biersack, HJ
Moller, HJ
机构
[1] Univ Halle Wittenberg, Psychiat Klin & Poliklin, D-06097 Halle, Germany
[2] Univ Bonn, Inst Klin & Expt Nukl Med, D-5300 Bonn, Germany
[3] Univ Vienna, Abt Allgemeine Psychiat, A-1010 Vienna, Austria
[4] Univ Munich, Psychiat Klin, D-80539 Munich, Germany
关键词
D O I
10.1055/s-2007-979321
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to compare striatal D-2 dopamine receptor occupancy of various typical neuroleptics and clozapine in relation to the occurrence of extrapyramidal side effects (EPS). Forty-four inpatients with schizophrenia, including 12 patients with schizodominant schizoaffective disorder, were evaluated using I-123-iodobenzamide (IBZM) and single photon emission computed tomography. Striatal D-2 dopamine receptor occupancy was estimated by use of a striatal/frontal cortex ratio (ST/FC) of IBZM binding. Fourteen patients were neuroleptic-free and served as controls. Six patients were treated with clozapine and 24 patients were treated with various typical neuroleptics. ST/FC ratios in patients taking typical neuroleptics were significantly lower than those who were neuroleptic free or treated with clozapine. Patients with EPS had lower ST/FC ratios than those without EPS. A significant linear relationship between ST/FC ratios and severity of EPS estimated by the Simpson-Angus-Scale was established (r=-0.51, p=0.041).
引用
收藏
页码:159 / 162
页数:4
相关论文
共 26 条
  • [1] [Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
  • [2] STRIATAL DOPAMINE RECEPTOR OCCUPANCY DURING AND FOLLOWING WITHDRAWAL FROM NEUROLEPTIC TREATMENT - CORRELATIVE EVALUATION BY POSITRON EMISSION TOMOGRAPHY AND PLASMA PROLACTIN LEVELS
    BARON, JC
    MARTINOT, JL
    CAMBON, H
    BOULENGER, JP
    POIRIER, MF
    CAILLARD, V
    BLIN, J
    HURET, JD
    LOCH, C
    MAZIERE, B
    [J]. PSYCHOPHARMACOLOGY, 1989, 99 (04) : 463 - 472
  • [3] BROICH K, 1992, Journal of Nuclear Medicine, V33, P898
  • [4] BRUCKE T, 1993, ADV NEUROL, V60, P494
  • [5] STRIATAL DOPAMINE D2-RECEPTOR BLOCKADE BY TYPICAL AND ATYPICAL NEUROLEPTICS
    BRUCKE, T
    ROTH, J
    PODREKA, I
    STROBL, R
    WENGER, S
    ASENBAUM, S
    [J]. LANCET, 1992, 339 (8791) : 497 - 497
  • [6] BRUCKE T, 1991, J CEREBR BLOOD F MET, V11, P220
  • [7] DOPAMINE D-2 RECEPTOR BLOCKADE IN-VIVO WITH THE NOVEL ANTIPSYCHOTICS RISPERIDONE AND REMOXIPRIDE - AN I-123 IBZM SINGLE-PHOTON EMISSION TOMOGRAPHY (SPET) STUDY
    BUSATTO, GF
    PILOWSKY, LS
    COSTA, DC
    ELL, PJ
    VERHOEFF, NPLG
    KERWIN, RW
    [J]. PSYCHOPHARMACOLOGY, 1995, 117 (01) : 55 - 61
  • [8] INVIVO ASSAY FOR NEUROLEPTIC RECEPTOR-BINDING IN THE STRIATUM - POSITRON TOMOGRAPHY IN HUMANS
    CAMBON, H
    BARON, JC
    BOULENGER, JP
    LOCH, C
    ZARIFIAN, E
    MAZIERE, B
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1987, 151 : 824 - 830
  • [9] IN VIVO CHARACTERISATION OF 3-IODO-6-METHOXYBENZAMIDE I-123 IN HUMANS
    COSTA, DC
    VERHOEFF, NPLG
    CULLUM, ID
    ELL, PJ
    SYED, GMS
    BARRETT, J
    PALAZIDOU, E
    TOONE, B
    VANROYEN, E
    BOBELDIJK, M
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1990, 16 (11): : 813 - 816
  • [10] FARDE L, 1992, ARZNEIMITTEL-FORSCH, V42-1, P260